Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study

Barbara Hasse, Bruno Ledergerber, Hansjakob Furrer et al. · Clinical Infectious Diseases · 2011 · 614 citations · Full text

Education, Geriatric Medicine, Aging +16

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

Grace A. McComsey, Douglas Kitch, Eric S. Daar et al. · The Journal of Infectious Diseases · 2011 · 497 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

Changes in Bone Mineral Density with Age in Men and Women: A Longitudinal Study

L. Warming, Christian Hassager, Claus Christiansen · Osteoporosis International · 2002 · 382 citations

Medicine, Geriatric Medicine, Orthopedic Surgery +14

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

Pharmacy, Pharmacology, Pharmacotherapy +17